Oncotelic Therapeutics Inc. (OTCQB: OTLC) used Drug Discovery 2026 in Burlingame, California, to showcase how artificial intelligence can bridge the gap between the vast expanse of biomedical literature and the practical work of developing new therapeutics. The company presented its PDAOAI discovery platform and a case study in hepatocellular carcinoma (HCC), demonstrating a development strategy that connects computational evidence gathering with hypothesis generation for further investigation.
Scott Myers, Oncotelic's Product Manager, delivered a presentation on October 7 titled "The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development." Myers explained how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts, providing researchers with a focused way to navigate the overwhelming volume of published science. The platform's ability to aggregate and structure biomedical knowledge addresses a critical bottleneck in drug development: the difficulty of extracting actionable insights from an ever-expanding body of literature.
The following day, Saran Saund, Chief Business Officer, presented an HCC case study that illustrated the platform's practical application. Saund described how disease-specific literature analysis led to the identification of a four-gene mTOR-related signature associated with survival. This signature was validated in an exploratory discovery analysis and an independent Japanese cohort, suggesting that PDAOAI can generate hypotheses that hold up across different populations. The work underscores the potential of AI-driven approaches to uncover novel biomarkers and therapeutic targets in oncology, where understanding the molecular underpinnings of disease is essential for developing effective treatments.
The implications of these presentations extend beyond the technical achievements. Oncotelic's participation in Drug Discovery 2026 highlights the growing role of AI in pharmaceutical research, where companies are increasingly leveraging computational tools to speed up discovery and reduce costs. The PDAOAI platform, by making sense of millions of abstracts, could help researchers prioritize targets and design better experiments, ultimately accelerating the translation of basic science into clinical candidates.
Moreover, the company's BIO REBOOT initiative, mentioned in the presentation, connects the platform's research capabilities with potential funding and development support for selected projects. This integration of research and funding mechanisms could provide a pathway for academic and early-stage projects to advance toward commercialization, addressing the notorious "valley of death" between discovery and clinical development.
For investors, the news matters because it positions Oncotelic at the intersection of two major trends: the use of AI in drug discovery and the focus on precision oncology. The latest news and updates relating to OTLC are available in the company's newsroom at ibn.fm/OTLC. The presentations also serve as a public demonstration of the company's technological capabilities, which could attract partnerships or licensing opportunities. As the pharmaceutical industry continues to embrace digital transformation, platforms like PDAOAI that can efficiently mine biomedical knowledge may become valuable assets.
InvestorWire, a specialized communications platform, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. These channels help ensure that developments like Oncotelic's reach a wide audience of investors and industry stakeholders.
The long-term impact of Oncotelic's approach will depend on whether the insights generated by PDAOAI can be translated into successful clinical programs. However, the company's efforts to combine AI-driven discovery with a structured path to funding and development represent a notable attempt to streamline the drug development process. If successful, this model could be adopted by other companies seeking to harness the power of big data and machine learning in the fight against cancer and other diseases.
